Allotment of Securities

Date: October 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers Plot No. C/1, G Block, Dalal Street, Fort Bandra–Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Maharashtra, India Symbol: NATCOPHARM Scrip Code: 524816 Dear Sir(s)/Madam(s), Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended in relation to Allotment of Equity Shares pursuant to the Rights Issue of Equity Shares of the Company (“Rights Issue”) This is in continuation to the meeting of the Board of Directors (“Board”) of Natco Pharma Limited (“Company”) held on September 9, 2026, approving the offer and issue of Equity Shares of the Company (“Equity Shares”) on a Rights Basis to eligible Equity Shareholders of the Company (“Issue”) and our intimation dated September 25, 2026 regarding the outcome of the meeting of the Board approving the various terms of the Issue and the meeting of the Fund Raising Committee held on September 28, 2026 approving the Letter of Offer. In relation to the aforesaid Issue and pursuant to the finalization of the basis of allotment of the Issue, in consultation with the Designated Stock Exchange i.e., National Stock Exchange of India Limited, the Fund Raising Committee at its meeting held today, i.e., October 23, 2026, inter alia, considered and approved the allotment of 1,70,58,082 Equity Shares at a price of ₹750 per Equity Share (including a premium of ₹748 per Equity Share) (“Allotment”). Accordingly, pursuant to the Allotment, the paid-up equity share capital of the Company has increased from ₹35,82,19,740, comprising of 17,91,09,870 fully paid-up equity shares of face value of ₹2 each, to ₹39,23,35,904 comprising of 19,61,67,952 fully paid-up equity shares of face value of ₹2 each. The meeting of the Fund-raising Committee commenced at 8.30 p.m. and completed at 8.55 p.m. The above information will be available on the website of the Company i.e. https://files.natcopharma.co.in/investor-relations/rights-issue-2026/ Thanking you, Yours faithfully, For Natco Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer